CrEAM-HD- At a Glance
  • Sponsored by : University Hospital, Lille
  • Official Title: Is Caffeine an Environmental Modifier in Huntington’s Disease?
  • Involves:Neurological, neuropsychological, neuroimaging evaluation and biological sample
  • Study type: Clinical Observational trial
  • phase: Not applicable 
  • Purpose : The aim of the study is to establish if caffeine consumption is associated with the evolution of the disease in premanifest HD.
  • Status: see trial sites below for details on recruitment status

 

Eligibility Criteria

Ages Eligible for Study:  21Years and older  (Adult, Older Adult)
Sexes Eligible for Study:  All
Accepts Healthy Volunteers: No

 

Inclusion Criteria

  • HD mutation carriers (>36 CAG)
  • premanifest (total motor UHDRS < 5)
  • estimated time to diagnosis between 3 and 10 years
  • adults older than 21 years (in order to exclude juvenile patients who begin the disease before 21 years)
  • informed consent signed
  • with a social protection

Exclusion Criteria

  • MRI contraindication
  • pregnant and lactating women
  • People under guardianship, trusteeship, deprive of freedom

 

TRIAL SITES

 

FRANCE

 

Trial site: Hôpital Roger Salengro, CHRU.

 

Status: Recruiting 

Address: Lille, France

 

 

Contact: Not Available at the moment

 

Telephone: Not Available at the moment

 

Email:  Not Available at the moment